Breaking News

Moderna Leads Coronavirus Vaccine Charge

First participant dosed in NIH-led Phase 1 study of mRNA vaccine against novel coronavirus

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Clinical-stage biotech Moderna announced that the first participant has been dosed in the Phase 1 study of the company’s mRNA vaccine (mRNA-1273) against the novel coronavirus (SARS-CoV-2). This Phase 1 study is being conducted by the National Institutes of Health (NIH) under its own Investigational New Drug (IND) application.   mRNA-1273 is an mRNA vaccine against SARS-CoV-2 encoding for a prefusion stabilized form of the Spike (S) protein, which was selected by Moderna in collaboration with ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters